SINDROM RAZDRAZhENNOGO KIShEChNIKA: MOZhNO LI DOSTICh' EFFEKTA MINIMAL'NYM LEKARSTVENNYM VOZDEYSTVIEM?
- Authors: Eremina E.Y.1
-
Affiliations:
- N.P. Ogarev Mordovia State University
- Issue: No 2 (2015)
- Pages: 64-71
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277274
- ID: 277274
Cite item
Open Access
Access granted
Abstract
The article presents current data on the mechanisms of pathogenesis and clinical variants of irritable bowel syndrome (IBS). Particular attention is given to an inflammation in the genesis of the disease. It was stressed that IBS is now seen not as a purely functional disorder, but as inflammation of the intestine with minimal changes in the mucous membrane. In this regard, it justified to use of a complex preparation of Kolofort, which has a positive impact on the development of the basic mechanisms and clinical symptoms of IBS. Comprehensive action is observed due to its three components: affinity-purified release-active brain-specific proteins with antibodies to S-100, histamine and tumor necrosis factor a. The results of a multicenter double-blind placebo-controlled randomized clinical studies have shown that Kolofort has a pronounced analgesic effect in patients with all types of IBS, which developed during the first 2 weeks of therapy. It was found that a decrease in the severity of abdominal pain syndrome and restore the motor-evacuation function of the gastrointestinal tract during treatment with Kolofort was due to the impact of both the central and the peripheral pathogenesis of IBS, visceral hypersensitivity and hyperalgesia, subclinical inflammation and physiological disorders.
Full Text
About the authors
Elena Yurevna Eremina
N.P. Ogarev Mordovia State University
Email: eeu61@mail.ru
MD, Professor, Head of the Department of Internal Medicine Propaedeutics 430005, Republic of Mordovia, Saransk, 68 Bolshevistskaya St
References
- Rome III Diagnostic Criteria for functional Gastrointestinal Disorders. Appendix A. Gastroenterology. 2006;20(5):885-99.
- Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional Bowel Disorders. Gastroentero-logy.2006; 130(5):1480-91.
- Spiller R., Aziz Q., Creed F., Emmanuel A., Houghton L., Hungin P., Jones R., Kumar D., Rubin G., Trudgill N., Whorwell P. Gudelines on the irritable bowel syndrome: mecanism and practical management. Gut. 2007;56:1770-98.
- WGO. Practice guideline - Irritable bowel syndrome: a global perspective. April, 2009.
- Парфенов А. И., Ручкина И.Н. Постинфекционный синдром раздраженного кишечника. Лечащий врач. 2010;7:16-9.
- McKeown E.S., Parry S.D., Stansfield R., Barton J.R., Welfare M.R. Postinfectious irritable bowel syndrome may occur after nongastrointestinal and intestinal infection. Neurogastroenterol. Motil. 2006;18:839-43.
- Park H. The pathophysiology of irritable bowel syndrome: inflammation and motor disorder. Korean J. Gastroenterol. 2006;47(2):101 -10.
- Ohman L., Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 2010;7(3):163-73.
- Fichna J., Storr M.A. Brain-Gut Interactions in IBS. Front Pharmacol. 2012;5(3):127.
- Осадчук М.А., Бурдина В.О. Новые патогенетические подходы к терапии синдрома раздраженного кишечника, основанные на морфофункциональных особенностях патологии. Практ. медицина. 2014;1 (77):12-20.
- Gwee K.A., Collin S.M., Read N.W. Increased rectal mucosal expression of winterleukin 1, in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523-6.
- Kim H.S, Lim J.H., Park H., Lee S.I. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute shigella infection - an observation in a small case control study. Yonsei Med. J. 2010;51(1):45-51.
- Däbritz J., Musci J., Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J. Gastroenterol. 2014;14(2):363-75.
- Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., Corinaldesi R., Stanghellini V. The immune system in irritable bowel syndrome. J. Neurogastroenterol. Motil. 2011 ;17(4):349-59.
- Akiho H., Ihara E., Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J. Gastrointest. Pathophysiol. 2010;1 (3) :97-105.
- Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Ardid D. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2012;36(11 -12) :1009-31.
- Castagne V., Lemaire M., Kheyfets I., Dugina J.L., Sergeeva S.A., Epstein O.I. Antibodies to S100 proteins have anxioly-tic-like activity at ultra-low doses in the adult rat. J. Pharm. Pharmacol. 2008;60(3):309-16.
- Крылова С.Г., Разина Т.Г., Зуева Е.П., Амосова Е.Н., Шилова Н.В., Дугина Ю.Л., Эпштейн О.И. Анальгезирующая и противовоспалительная активность антител к гистамину в эксперименте. Бюллетень экспериментальной биологии. 2002; прил. 4:95-7.
- Эпштейн О.И. Сверхмалые дозы (история одного исследования). М.: Изд-во РАМН. 2008:336 с.
- Эртузун И.А., Зуева Е.П., Крылова С.Г., Ефимова Л.А., Дугина Ю.Л., Эпштейн О.И. Экспериментальное изучение Колофорта - нового препарата для лечения синдрома раздраженного кишечника и других функциональных заболеваний желудочнокишечного тракта. Вестник ВолгГМУ. 2012; вып. 4(44):25-7.
- Авалуева Е.Б., Адашева Т.В., Бабаева А.Р., Бурдина Е.Г., Киреева Н.В., Ленская Л.Г., Осадчук М.А., Пахомова И.Г., Попова Л.И., Ткаченко Е.И., Успенский Ю.П., Шварц Ю.Г., Мысливец А.А., Андрианова Е.Н. Эффективность и безопасность применения Колофорта при синдроме раздраженного кишечника: итоги многоцентрового двойного слепого плацебоконтролируемого рандомизированного клинического исследования. Приложение Consilium Medicum (Гастроэнтерология). 2014;1:36-43.
Supplementary files
